NASDAQ:HROW

Harrow Health - HROW Stock Forecast, Price & News

$12.38

+0.33 (+2.74%)

(As of 12/2/2022 09:00 PM ET)

Add

Compare

Today's Range: $11.90
▼
$12.51
50-Day Range: $7.61
▼
$12.82
52-Week Range: $5.40
▼
$13.29

Volume: 151,900 shs
Average Volume: 119,576 shs
Market Capitalization: $335.13 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $17.00

Harrow Health MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 37.3% Upside
$17.00 Price Target
Short Interest: Bearish
4.04% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.90
Based on 3 Articles This Week
Insider Trading: Selling Shares
$504,800 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.53) to ($0.03) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

386th out of 1,033 stocks

Pharmaceutical Preparations Industry

159th out of 502 stocks

3.5

Analyst's Opinion

Consensus Rating
Harrow Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $17.00, Harrow Health has a forecasted upside of 37.3% from its current price of $12.38.
Amount of Analyst Coverage
Harrow Health has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
4.04% of the float of Harrow Health has been sold short.
Short Interest Ratio / Days to Cover
Harrow Health has a short interest ratio ("days to cover") of 4.9.
Change versus previous month
Short interest in Harrow Health has recently increased by 15.80%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Harrow Health does not currently pay a dividend.
Dividend Growth
Harrow Health does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for HROW.

2.7

News and Social Media Coverage

News Sentiment
Harrow Health has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.33 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Harrow Health this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for HROW on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Harrow Health to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Harrow Health insiders have sold 366.11% more of their company's stock than they have bought. Specifically, they have bought $108,300.00 in company stock and sold $504,800.00 in company stock.
Percentage Held by Insiders
14.26% of the stock of Harrow Health is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
59.83% of the stock of Harrow Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Harrow Health are expected to grow in the coming year, from ($0.53) to ($0.03) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Harrow Health is -14.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Harrow Health is -14.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Harrow Health has a P/B Ratio of 30.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Harrow Health (NASDAQ:HROW) Stock

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

Receive HROW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harrow Health and its competitors with MarketBeat's FREE daily newsletter.

HROW Stock News Headlines

November 30, 2022 | finance.yahoo.com

Harrow and iOR Partners Expand National Product Supply Agreement

November 16, 2022 | finance.yahoo.com

Harrow Health Third Quarter 2022 Earnings: Misses Expectations

October 28, 2022 | finance.yahoo.com

Harrow to Announce Third Quarter 2022 Financial Results on November 14, 2022

October 27, 2022 | finance.yahoo.com

Melt Pharmaceuticals Announces Dosing of Last Patient in Phase 2 Pivotal Efficacy and Safety Study for MELT-300

October 13, 2022 | finance.yahoo.com

Harrow Health, Inc. (NASDAQ:HROW) has caught the attention of institutional investors who hold a sizeable 48% stake

October 6, 2022 | finance.yahoo.com

Harrow Health sells part of company for up to $10.5 million

October 5, 2022 | finance.yahoo.com

Harrow Sells Non-Ophthalmic Compounding Business

September 29, 2022 | finance.yahoo.com

ImprimisRx Launches Fortisite™ (Tobramycin 1.5% + Vancomycin 5%) Compounded Antibiotic Formulation

September 28, 2022 | finance.yahoo.com

FDA Approves First Branded Ocular Anesthetic In Almost 14 Years

September 27, 2022 | finance.yahoo.com

Harrow Announces U.S. FDA Approval of IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia

September 21, 2022 | seekingalpha.com

HROW Harrow Health, Inc.

September 21, 2022 | finance.yahoo.com

Melt Pharmaceuticals files for IPO

August 27, 2022 | finance.yahoo.com

Is Harrow Health (HROW) a Wise Investment Choice?

August 19, 2022 | seekingalpha.com

SRK Capital - Harrow Health: Market Missing The Forest For The Trees

August 11, 2022 | finance.yahoo.com

Harrow Health to Participate in H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

July 27, 2022 | finance.yahoo.com

Harrow Health to Announce Second Quarter 2022 Financial Results on August 9, 2022

July 16, 2022 | uk.finance.yahoo.com

Harrow Health, Inc. (HROW)

July 16, 2022 | finance.yahoo.com

Harrow Health's (NASDAQ:HROW) investors will be pleased with their stellar 151% return over the last five years

May 26, 2022 | seekingalpha.com

Harrow Health files for $300M mixed shelf offering

May 8, 2022 | seekingalpha.com

Harrow Health's (HROW) CEO Mark L. Baum on Q1 2022 Results - Earnings Call Transcript

May 6, 2022 | seekingalpha.com

Harrow Health, Inc. 2022 Q1 - Results - Earnings Call Presentation

May 6, 2022 | finance.yahoo.com

Is Harrow Health, Inc.'s (NASDAQ:HROW) Shareholder Ownership Skewed Towards Insiders?

May 4, 2022 | finance.yahoo.com

Melt Pharmaceuticals Announces MELT-210 Top-Line Results of Phase 1 Pharmacokinetics (PK) Study for Procedural Sedation

April 20, 2022 | finance.yahoo.com

Harrow Health to Announce First Quarter 2022 Financial Results on May 5, 2022

March 31, 2022 | finance.yahoo.com

Harrow Health Announces Appointments to Its Board of Directors

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive HROW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harrow Health and its competitors with MarketBeat's FREE daily newsletter.

HROW Company Calendar

Last Earnings: 11/09/2021
Today: 12/05/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/09/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:HROW
CUSIP: N/A
CIK: 1360214
Web: www.harrowinc.com
Phone: (615) 733-4730
Fax: 858-345-1745
Employees: 182
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $17.00
High Stock Price Forecast: $17.00
Low Stock Price Forecast: $17.00
Forecasted Upside/Downside: +37.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.83)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-18,010,000.00
Net Margins: -25.50%
Pretax Margin: -25.27%
Return on Equity: -11.57%
Return on Assets: -0.79%

Debt

Debt-to-Equity Ratio: 83.80
Current Ratio: 3.49
Quick Ratio: 3.20

Sales & Book Value

Annual Sales: $72.48 million
Price / Sales: 4.62
Cash Flow: $0.06 per share
Price / Cash Flow: 196.43
Book Value: $0.41 per share
Price / Book: 30.20

Miscellaneous

Outstanding Shares: 27,070,000
Free Float: 23,210,000
Market Cap: $335.13 million
Optionable: Optionable
Beta: 0.36

Key Executives

Mr. Mark L. Baum J.D. (Age 49)
CEO & Chairman
Comp: $1.07M

Mr. Andrew R. Boll C.F.A. (Age 40)
C.M.A., CFA, CMA, CFO & Corp. Sec.
Comp: $716.73k

Dr. Robert J. Kammer D.D.S. (Age 73)
Special Advisor
Comp: $91.88k

Mr. John P. Saharek MBA (Age 62)
Chief Commercial Officer
Comp: $621.92k

Jamie Webb
Director of Communications & Investor Relations

Dr. Dennis E Saadeh Pharm.D.
Chief of Formulation Strategy

Mr. Andrew Livingston
Chief Innovation Officer

Ms. Kim Barratt
Chief Talent Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

HROW Stock - Frequently Asked Questions

Should I buy or sell Harrow Health stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harrow Health in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" HROW shares.
View HROW analyst ratings or view top-rated stocks.
What is Harrow Health's stock price forecast for 2023?: 1 Wall Street research analysts have issued twelve-month price targets for Harrow Health's stock. Their HROW share price forecasts range from $17.00 to $17.00. On average, they expect the company's stock price to reach $17.00 in the next year. This suggests a possible upside of 37.3% from the stock's current price.
View analysts price targets for HROW or view top-rated stocks among Wall Street analysts.
How have HROW shares performed in 2022?: Harrow Health's stock was trading at $8.64 at the beginning of 2022. Since then, HROW stock has increased by 43.3% and is now trading at $12.38.
View the best growth stocks for 2022 here.
Are investors shorting Harrow Health?: Harrow Health saw a increase in short interest in November. As of November 15th, there was short interest totaling 993,800 shares, an increase of 15.8% from the October 31st total of 858,200 shares. Based on an average daily volume of 201,200 shares, the short-interest ratio is presently 4.9 days. Approximately 4.0% of the company's shares are sold short.
View Harrow Health's Short Interest.
When is Harrow Health's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our HROW earnings forecast.
How were Harrow Health's earnings last quarter?: Harrow Health, Inc. (NASDAQ:HROW) announced its earnings results on Tuesday, November, 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by $0.34. The company earned $18.71 million during the quarter, compared to the consensus estimate of $17.27 million. Harrow Health had a negative trailing twelve-month return on equity of 11.57% and a negative net margin of 25.50%. During the same quarter last year, the firm earned $0.32 EPS.

What other stocks do shareholders of Harrow Health own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Harrow Health investors own include NVIDIA (NVDA), Aldeyra Therapeutics (ALDX), OPKO Health (OPK), QUALCOMM (QCOM), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), VBI Vaccines (VBIV), Exelixis (EXEL) and Mustang Bio (MBIO).
What is Harrow Health's stock symbol?: Harrow Health trades on the NASDAQ under the ticker symbol "HROW."
Who are Harrow Health's major shareholders?: Harrow Health's stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (4.11%), Private Capital Management LLC (3.80%), Ophir Asset Management Pty Ltd (3.17%), Uniplan Investment Counsel Inc. (2.56%), Invenire Partners LP (1.68%) and BlackRock Inc. (1.61%). Insiders that own company stock include David P Kennedy, Opaleye Management Inc, Richard L Md Lindstrom and Richard L Md Lindstrom.
View institutional ownership trends.
How do I buy shares of Harrow Health?: Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Harrow Health's stock price today?: One share of HROW stock can currently be purchased for approximately $12.38.
How much money does Harrow Health make?: Harrow Health (NASDAQ:HROW) has a market capitalization of $335.13 million and generates $72.48 million in revenue each year. The company earns $-18,010,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis.
How many employees does Harrow Health have?: The company employs 182 workers across the globe.
How can I contact Harrow Health?: Harrow Health's mailing address is 102 Woodmont Blvd. Suite 610, Nashville TN, 37205. The official website for the company is www.harrowinc.com. The company can be reached via phone at (615) 733-4730, via email at jwebb@harrowinc.com, or via fax at 858-345-1745.

This page (NASDAQ:HROW) was last updated on 12/5/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial